Phase 3 Recruiting NIH
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in Ohio: - Indu and Raj Soin Medical Center — Beavercreek, Ohio
- Strecker Cancer Center-Belpre — Belpre, Ohio
- Saint Elizabeth Boardman Hospital — Boardman, Ohio
- Cleveland Clinic Mercy Hospital — Canton, Ohio
- Dayton Physicians LLC-Miami Valley South — Centerville, Ohio
Phase 3 Recruiting NIH
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Sites in Ohio: - Children's Hospital Medical Center of Akron — Akron, Ohio
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- Rainbow Babies and Childrens Hospital — Cleveland, Ohio
- Cleveland Clinic Foundation — Cleveland, Ohio
- Nationwide Children's Hospital — Columbus, Ohio
Phase 3 Recruiting Network
This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with peripheral T-cell lymphoma who achieved a complete response after initial chemotherapy. U…
Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT06724237
Sites in Ohio: - OhioHealth O'Bleness Hospital — Athens, Ohio
- Columbus Oncology and Hematology Associates Inc — Columbus, Ohio
- Riverside Methodist Hospital — Columbus, Ohio
- Grant Medical Center — Columbus, Ohio
- Doctors Hospital — Columbus, Ohio
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation. Temozolomide is in a class of medications …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07215910
Sites in Ohio: - University of Cincinnati Cancer Center-UC Medical Center — Cincinnati, Ohio
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- University of Cincinnati Cancer Center-West Chester — West Chester, Ohio
Phase 3 Recruiting Industry
This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard …
Sponsor: AstraZeneca
NCT ID: NCT06549595
Sites in Ohio: - Research Site — Blue Ash, Ohio
- Research Site — Cincinnati, Ohio
- Research Site — Columbus, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of tacabrutideg alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had…
Sponsor: BeOne Medicines
NCT ID: NCT06973187
Sites in Ohio: - Dayton Physician Network — Dayton, Ohio
Phase 3 Recruiting Industry
The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of son…
Sponsor: BeOne Medicines
NCT ID: NCT06742996
Sites in Ohio: - University Hospitals — Cleveland, Ohio
- Cleveland Clinic Foundation — Cleveland, Ohio
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- Ohio Health Research Institute — Columbus, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting o…
Sponsor: Pierre Fabre Medicament
NCT ID: NCT03394365
Sites in Ohio: - Cleveland Clinic Foundation (Adults and Pediatrics) — Cleveland, Ohio
- Nationwide Children's Hospital (Pediatrics only) — Columbus, Ohio
- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (Adults and Pediatrics) — Columbus, Ohio
Phase 3 Recruiting Industry
A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell ly…
Sponsor: Corvus Pharmaceuticals, Inc.
NCT ID: NCT06561048
Sites in Ohio: - The Ohio State University — Columbus, Ohio
Phase 3 Recruiting Industry
This is a Phase 3, randomized, open-label, multicenter study comparing rocbrutinib (LP-168) versus pirtobrutinib in adult participants with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who h…
Sponsor: Newave Pharmaceutical Inc
NCT ID: NCT07342478
Sites in Ohio: - OSU Comprehensive Cancer Center — Columbus, Ohio
Phase 3 Recruiting Academic/Other
The researchers are doing this study to find out whether PK-targeted fludarabine is an effective Lymphodepletion (LD) chemotherapy approach for people with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) who will receive ti…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07223021
Sites in Ohio: - Cincinnati Children's Hospital Medical Center (Data Collection Only) — Cincinnati, Ohio
Phase 2 Recruiting NIH
This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab or zanubrutinib in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutin…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04840602
Sites in Ohio: - Strecker Cancer Center-Belpre — Belpre, Ohio
- Adena Regional Medical Center — Chillicothe, Ohio
- Mount Carmel East Hospital — Columbus, Ohio
- Columbus Oncology and Hematology Associates Inc — Columbus, Ohio
- Riverside Methodist Hospital — Columbus, Ohio
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Ohio: - Children's Hospital Medical Center of Akron — Akron, Ohio
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- Rainbow Babies and Childrens Hospital — Cleveland, Ohio
- Dayton Children's Hospital — Dayton, Ohio
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital — Toledo, Ohio
Phase 2 Recruiting NIH
This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and BCL2 rearran…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06649812
Sites in Ohio: - Aultman Health Foundation — Canton, Ohio
- University of Cincinnati Cancer Center-UC Medical Center — Cincinnati, Ohio
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- University of Cincinnati Cancer Center-West Chester — West Chester, Ohio
Phase 2 Recruiting Industry
Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still ma…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06890884
Sites in Ohio: - University of Cincinnati Medical Center ( Site 0156) — Cincinnati, Ohio
- University Hospitals of Cleveland ( Site 0155) — Cleveland, Ohio
- Fairview Hospital-Moll Cancer Center ( Site 0198) — Cleveland, Ohio
- Cleveland Clinic Main ( Site 0101) — Cleveland, Ohio
- Cleveland Clinic - Hillcrest Hospital-Hillcrest Hospital Cancer Center ( Site 0199) — Mayfield Heights, Ohio
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Ohio: - Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD…
Sponsor: Lyell Immunopharma, Inc.
NCT ID: NCT05826535
Sites in Ohio: - University of Cincinnati (UC) Physicians Company, LLC — Cincinnati, Ohio
- Cleveland Clinic — Cleveland, Ohio
Phase 2 Recruiting Industry
DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory B cell lymphoma (BCL). Cohorts includ…
Sponsor: Miltenyi Biomedicine GmbH
NCT ID: NCT04792489
Sites in Ohio: - The Ohio State University Wexner Medical Center James Cancer — Columbus, Ohio
Phase 1, Phase 2 Recruiting Industry
This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult participants with relapsed or refractory…
Sponsor: Curis, Inc.
NCT ID: NCT03328078
Sites in Ohio: - Cleveland Clinic — Cleveland, Ohio
Phase 2 Recruiting Industry
This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of surovatamig (AZD0486) monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have receive…
Sponsor: AstraZeneca
NCT ID: NCT06526793
Sites in Ohio: - Research Site — Columbus, Ohio
Phase 1, Phase 2 Recruiting Industry
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- posi…
Sponsor: Nuvalent Inc.
NCT ID: NCT05384626
Sites in Ohio: - OSU Brain & Spine Hospital — Columbus, Ohio
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety and efficacy of surovatamig (formerly AZD0486) administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies
Sponsor: AstraZeneca
NCT ID: NCT06564038
Sites in Ohio: - Research Site — Columbus, Ohio
Phase 2 Recruiting Industry
This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon two-stage optimal design.
Sponsor: March Biosciences Inc
NCT ID: NCT06534060
Sites in Ohio: - Cleveland Clinic — Cleveland, Ohio
Phase 1, Phase 2 Recruiting Industry
This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid mali…
Sponsor: AVM Biotechnology Inc
NCT ID: NCT04329728
Sites in Ohio: - Gabrail Cancer Center Research, — Canton, Ohio
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
Sponsor: Vironexis Biotherapeutics Inc.
NCT ID: NCT06533579
Sites in Ohio: - The Ohio State University Wexner Medical Center — Columbus, Ohio